Skip to main content
SpringerLink
Log in

Central dopaminergic properties of HW-165 and its enantiomers; Trans-octahydrobenzo(f)quinoline congeners of 3-PPP

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

In the further development of CNS dopamine autoreceptor active compounds related to 3-PPP, the trans-fused 7-hydroxy-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinoline HW-165 and its enantiomers were synthesised. This paper describes the basic pharmacological properties of these latter, novel “atypical” dopaminergic agents, based on an extensive series of biochemical and behavioural experiments in rats.

By and large, the pharmacological activities of HW-165—essentially, if not exclusively, residing in its (4aS,10bS)-(−)-enantiomer—were similar to those displayed by (S)-(−)-3-PPP, indicating the simultaneous presence of central dopamine (autoreceptor) agonist and weak (postsynaptic) antagonist properties in the molecule. Thus, in non-pretreated animals HW-165 and its active species monotonically suppressed the spontaneous locomotion without causing catalepsy or other appreciable motor disabilities, and at the same time selectively reduced the dopamine synthesis, release/turnover and utilisation. Some differences in these biochemical responses to HW-165 [racemate or (−)-enantiomer] were, however, noted in the limbic vs. striatal brain areas (e.g. decrease of dopamine synthesis particularly in the limbic parts). On the other hand, while failing to reverse reserpine-induced akinesia or to elicit stereotyped behaviour, the agents markedly inhibited the dopamine synthesis in either of the dopamine-dominated cerebral regions in the reserpinised as well as in γ-butyrolactone (GBL)-treated rats. As shown for racemic HW-165 after reserpine pretreatment, the inhibition of dopamine synthesis was completely and sterecselectively blocked by (+)-butaclamol, thereby supporting direct dopamine receptor interaction. Racemic HW-165 readily antagonised the d-amphetamine-induced locomotor hyperactivity. Apomorphine-induced hyperactivity was, however, distinctly more resistant to antagonism by HW-165 [racemate or (−)-enantiomer]. Moreover, the latter agents fully prevented the apomorphine-induced inhibition of striatal dopamine synthesis in otherwise non-pretreated rats, while only partly counteracting this effect of apomorphine in the limbic regions of such animals, and in either brain area of rats treated with γ-butyro-lactone. The findings are interpreted within the context of the mixed dopamine agonist/antagonist properties (referred above) of HW-165 and its active (−)-species in relation to the adaptive state of central dopamine receptors and possible regional variations in feedback strength and organisation.

Taken together, for reasons discussed, the observations indicated that racemic and (−)-HW-165 may exert a preferential, net “limbic” anti-dopaminergic impact of action in normal animals. This interesting pharmacological profile might thus suggest the usefulness of these agents both as novel neuropsychopharmacological research tools and in the treatment of dopamine-related CNS disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahlenius S, Hillegaart V (1985) Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- or post-synaptic inhibition of dopaminergic. neurotransmission. Pharmacol Biochem Behav (in press)

  • Andén N-E (1980) Regulation of monoamine synthesis and utilization by receptors. In: Szekeres L (ed) Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 429–462

    Google Scholar 

  • Andén N-E, Golembiowska-Nikitin K, Thornström U (1982) Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn-Schmiedeberg's Arch Pharmacol 321:100–104

    Google Scholar 

  • Andén N-E, Grabowska-Andén M, Liljenberg B (1983a) Demonstration of autoreceptors on dopamine neurons in different brain regions of rats treated with gamma-butyrolactone. J Neural Transm 58:143–152

    Google Scholar 

  • Andén N-E, Grabowska-Andén M, Lindgren S, Thornström U (1983b) Synthesis rate of dopamine: Difference between corpus striatum and limbic system as a possible explanation of variations in reactions to drugs. Naunyn-Schmiedeberg's Arch Pharmacol 323:193–198

    Google Scholar 

  • Andén N-E, Nilsson H, Ros E, Thornström U (1983c) Effects of B-HT 920 and B-HT 93 on dopamine and noradrenaline autoreceptors in the rat brain. Acta Pharmacol Toxicol 52:51–56

    Google Scholar 

  • Andén N-E, Golembiowska-Nikitin K, Nilsson H, Ros E, Thornström U (1983d) Effects of two azepine derivatives (B-HT 920 and B-HT 933) on pre- and postsynaptic dopamine receptors in the brain. Acta Pharm Suec (Suppl. 1983: 1): 154–164

    Google Scholar 

  • Arnt J (1985) Behavioural studies of dopamine receptors: Evidence for regional selectivity and receptor multiplicity. In: Creese I, Fraser C (eds) Structure and function of dopamine receptors. Alan R Liss, New York, in press

    Google Scholar 

  • Arnt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60:205–223

    Google Scholar 

  • Arnt J, Bögesö KP, Christensen AV, Hyttel J, Larsen J-J, Svendsen O (1983) Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacology 81:199–207

    Google Scholar 

  • Carlsson A (1983) Dopamine receptor agonists: Intrinsic activity vs. state of the receptor. J Neural Transm 57:309–315

    Google Scholar 

  • Carlsson A (1985) Pharmacological properties of presynaptic dopamine receptor agonists. In: Casey DF, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia-research and treatment. Psychopharmacology, Suppl 2. Springer, Berlin Heidelberg New York Tokyo, pp 31–38

    Google Scholar 

  • Carlsson A, Lindqvist M (1973) Effects of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437–440

    Google Scholar 

  • Chiodo LA, Bunney BS (1983) Electrophysiological studies on EMD 23448, an indolyl-3-butylamine, in the rat: A putative selective dopamine autoreceptor agonist. Neuropharmacology 22:1087–1093

    Google Scholar 

  • Clark D, Carlsson A, Hjorth S, Svensson K, Engel J, Sanchez D (1982) Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioural studies. Eur J Pharmacol 83:131–134

    Google Scholar 

  • Clark D, Carlsson A, Hjorth S, Engel J, Lindberg P (1983a) The effect of the enantiomers of 3-PPP on conditioned avoidance in the rat. Psychopharmacology 81:14–17

    Google Scholar 

  • Clark D, Carlsson A, Hjorth S, Svensson K, Liljequist S, Engel J, Engberg G, Svensson T, Wikström H (1983b) Is 3-PPP a potential antipsychotic agent? Acta Pharm Suec (Suppl 1983: 1) pp 145–153

    Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1984) (+)- and (−)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. Eur J Pharmacol 106:185–189

    Google Scholar 

  • Clark D, Engberg G, Pileblad E, Svensson TH, Carlsson A, Freeman AS, Bunney BS (1985a) An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system. Naunyn-Schmiedeberg's Arch Pharmacol 329:344–354

    Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985b) Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62:1–52

    Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985c) Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62:171–207

    Google Scholar 

  • Corsini GU, Horowski R, Rainer E, Del Zompo M (1984) Treatment of Parkinson's disease with a dopamine partial agonist. Soc Neurosci Abstr 10:290 (Abstr no 88.6)

    Google Scholar 

  • Domesick VB (1980) The anatomical basis for feedback and feedforward in the striatonigral system. In: Gessa GL, Corsini GU (eds) Apomorphine and other dopaminomimetics, vol 1, Basic Pharmacology. Raven Press, New York, pp 27–39

    Google Scholar 

  • Eriksson E, Modigh K, Carlsson A, Wikström H (1983) Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. Eur J Pharmacol 96:29–36

    Google Scholar 

  • Eriksson E, Svensson K, Clark D (1985) The putative dopamine autoreceptor agonist B-HT 920 decreases nigral dopamine cell firing rate and prolactin release in rat. Life Sci 36:1819–1827

    Google Scholar 

  • Feenstra MGP, Rollema H, Mulder TBA, Westerink BHC, Horn AS (1983) In vivo dopamine receptor binding studies with a non-radioactively labelled agonist, dipropyl-5,6-ADTN. Life Sci 32:1313–1323

    Google Scholar 

  • Felice LJ, Felice JD, Kissinger PT (1978) Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography. J Neurochem 31:1461–1465

    Google Scholar 

  • Fielding S, Lal H (1978) Behavioural actions of neuroleptics. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of Psychopharmacology, vol 10. Plenum Press. New York, pp 91–128

    Google Scholar 

  • Fowler CJ, Thorell G, Andersson M, Magnusson O (1985) Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function? Naunyn-Schmiedeberg's Arch Pharmacol 331:12–19

    Google Scholar 

  • Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD (1980) An observational method for quantifying the behavioural effects of dopamine agonists: Contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69:253–259

    Google Scholar 

  • Grabowska-Andén M, Andén N-E (1983) Stimulation of postsynaptic DA2 receptor produces jerks in reserpine-treated rats. J Pharm Pharmacol 35:543–545

    Google Scholar 

  • Hjorth S (1983) On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. Acta Physiol Scand (Suppl. 517) 118:1–52

    Google Scholar 

  • Hjorth S, Carlsson A, Clark D, Svensson K, Wikström H, Sanchez D, Lindberg P, Hacksell U, Arvidsson L-E, Johansson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology 81:89–99

    Google Scholar 

  • Hjorth S, Svensson K, Carlsson A, Wikström H, Andersson B, Sanchez D, Arvidsson L-E, Nilsson JLG, Johansson AM (1984a) Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners to 3-PPP. Presented at the VIIIth Int Symp on Med Chem, Uppsala, Sweden, Aug. 27–31, 1984. Proceedings, in press

  • Hjorth S, Carlsson A, Clark D, Svensson K (1984b) Central dopaminergic actions of (+)- and (−)-3-PPP in relation to previous synaptic activity. Soc Neurosci Abstr 10:239

    Google Scholar 

  • Hjorth S, Clark D, Carlsson A (1985a) Lack of functional evidence for the involvement of sigma-opiate receptors in the actions of 3-PPP on central dopaminergic systems: Discrepancies between in vitro and in vivo findings. Life Sci 37:673–684

    Google Scholar 

  • Hjorth S, Clark D, Svensson K, Carlsson A, Thorberg O (1985b) Subchronic administration of (−)-3-PPP and central dopamine receptor sensitivity changes. J Neural Transm 64:187–198

    Google Scholar 

  • Hjorth S, Engel JA, Carlsson A (1986a) Anticonflict effect of low doses of the dopamine agonist apomorphine in the rat. Pharmacol Biochem Behav 24:237–240

    Google Scholar 

  • Hjorth S, Eriksson E, Andersson B (1986b) Stereoselective inhibition of prolactin secretion by (−)-HW-165, a novel 3-PPP congener; further support for similarities between central dopamine autoreceptors and pituitary lactotroph dopamine receptors. Eur J Pharmacol (in press)

  • Johansson AM, Arvidsson L-E, Hacksell U, Nilsson JLG, Svensson K, Hjorth S, Clark D, Carlsson A, Sanchez D, Andersson B, Wikström H (1985) Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. J Med Chem 28:1049–1053

    Google Scholar 

  • Kehr W (1974) Temporal changes in catecholamine synthesis of rat forebrain structures after axotomy. J Neural Transm 35:307–317

    Google Scholar 

  • Kehr W (1976) 3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 293:209–215

    Google Scholar 

  • Largent BL, Gundlach AL, Snyder SH (1984) Psychotomimetic opiate receptors labeled and visualized with (+)-(3H)3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc Natl Acad Sci USA 81:4983–4987

    Google Scholar 

  • Litchfield JT, Jr, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113

    Google Scholar 

  • Magnusson O, Nilsson LB, Westerlund D (1980) Simultaneous determination of dopamine, dopac and homovanillic acid. Direct injection of supernatants from brain homogenates in a liquid chromatography-electrochemical detection system. J Chromatogr 221:237–247

    Google Scholar 

  • Martin GE, Pettibone DJ (1985) Dopamine agonist activity of EMD 23,448. J Neural Transm 61:115–123

    Google Scholar 

  • Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry: Preclinical and clinical studies. Schizophrenia Bull 6:456–475

    Google Scholar 

  • Montanaro N, Vaccheri A, Dall'Olio R, Gandolfi O (1983) Time course of rat motility response to apomorphine: A simple model for studying preferential blockade of brain dopamine receptors mediating sedation. Psychopharmacology 81:214–219

    Google Scholar 

  • Roth RH, Murrin LC, Walters J (1976) Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid. Eur J Pharmacol 36:163–171

    Google Scholar 

  • Seyfried CA, Fuxe K, Wolf H-P, Agnati LF (1983) Neurochemical and functional studies with EMD 23448, a novel dopamine agonist, Acta Pharm Suec (Suppl 1983: 2) pp 243–247

    Google Scholar 

  • Shum A, Sole MJ, van Loon GR (1982) Simultaneous measurement of 5-hydroxytryptophan and l-dihydroxyphenylalanine by high-performance liquid chomatography with electrochemical detection. Measurement of serotonin and catecholamine turnover in discrete brain regions. J Chromatogr 228:123–130

    Google Scholar 

  • Strömbom U (1975) On the functional role of pre- and postsynaptic catecholamine receptors in brain. Acta Physiol Scand (Suppl 431): 1–43

    Google Scholar 

  • Strömbom UH, Liedman B (1982) Role of dopaminergic neurotransmission in locomotor stimulation by dexamphetamine and ethanol. Psychopharmacology 78:271–276

    Google Scholar 

  • Svensson K, Hjorth S, Clark D, Carlsson A, Wikström H, Andersson B, Sanchez D, Johansson AM, Arvidsson L-E, Hacksell U, Wilsson JLG (1986) (+)-UH 232 and (+)-UH 242: Novel stereoselective dopamine receptor agonists with preferential action on autoreceptors. J Neural Transm 65:1–27

    Google Scholar 

  • Tam SW, Cook L (1984) δ opiates and certain antipsychotic drugs mutually inhibit (+)-(3H)SKF 10,047 and (3H)-haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618–5621

    Google Scholar 

  • Van Oene JC, Houwing H, Dijkstra D, Horn AS (1983) trans-N-n-propyl-7-hydroxy-octahydrobenzo(f)quinoline, a rigid 3-PPP analogue with greater potency but lack of selectivity for dopamine autoreceptors. Eur J Pharmacol 87:491–495

    Google Scholar 

  • Wachtel H, Rettig K-J, Seltz A (1984) The central dopamine agonistic action of transdihydrolisuride is unmasked at supersensitive receptors. Naunyn-Schmiedeberg's Arch Pharmacol (Suppl) 325:R80

    Google Scholar 

  • Walters JR, Roth RH (1976) Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 296:5–14

    Google Scholar 

  • Wang RY (1981a) Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3:123–140

    Google Scholar 

  • Wang RY (1981b) Dopaminergic neurons in the rat ventral tegmental area. II. Evidence for autoregulation. Brain Res Rev 3:141–153

    Google Scholar 

  • Westerink BHC (1985) Sequence and significance of dopamine metabolism in the rat brain. Neurochem Int 7:221–227

    Google Scholar 

  • Wikström H, Sanchez D, Lindberg P, Arvidsson L-E, Hacksell U, Johansson A, Nilsson JLG, Hjorth S, Carlsson A (1982) Monophenolic octahydrobenzo(f)quinolines: Central dopamine- and serotonin-receptor stimulating activity. J Med Chem 25:925–931

    Google Scholar 

  • Wikström H, Sanchez D, Lindberg P, Hacksell U, Arvidsson L-E, Johansson A, Thorberg S-O, Nilsson JLG, Svensson K, Hjorth S, Clark D, Carlsson A (1984) Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: Central dopamine receptor activity. J Med Chem 27:1030–1036

    Google Scholar 

  • Wikström H, Andersson B, Sanchez D, Lindberg P, Arvidsson L-E, Johansson AM, Nilsson JLG, Svensson K, Hjorth S, Carlsson A (1985) Resolved monophenolic 2-aminotetralins and 1,2,3,4-4a,5,6,10b-octahydrobenzo(f)quinolines: Structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. J Med Chem 28:215–225

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Göteborg, P.O. Box 33031, S-40033, Göteborg, Sweden

    Stephan Hjorth, Kjell Svensson & Arvid Carlsson

  2. Organic Chemistry Unit, Department of Pharmacology, University of Göteborg, P.O. Box 33031, S-400 33, Göteborg, Sweden

    Håkan Wikström & Bengt Andersson

Authors
  1. Stephan Hjorth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kjell Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arvid Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Håkan Wikström
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bengt Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hjorth, S., Svensson, K., Carlsson, A. et al. Central dopaminergic properties of HW-165 and its enantiomers; Trans-octahydrobenzo(f)quinoline congeners of 3-PPP. Naunyn-Schmiedeberg's Arch. Pharmacol. 333, 205–218 (1986). https://doi.org/10.1007/BF00512931

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00512931

Key words

Search

Navigation